Cochlear Singapore launches its latest off-the-ear sound processor with advanced connectivity and proven hearing performance technology.
According to the World Health Organization, over 700 million people are estimated to have disabling hearing loss by 2050. That makes up to be one in every 10 people. Disabling hearing loss is characterised as a hearing loss greater than 35 decibels (dB), where the normal hearing threshold is 20 dB or better.
There are many causes of hearing loss and deafness, all of which can happen at various points in life: during childhood, pregnancy, and well into adulthood. Age-related hearing loss (or presbycusis) is the gradual loss of hearing over time. Globally, one in three adults over the age of 65 has hearing loss, yet only less than five per cent of people who may benefit from a hearing device have received one. In Singapore, an estimated 10 per cent of Singaporeans over the age of 60 suffer disabling hearing loss with only a little over three per cent of them with hearing aids.
In a study published in Annals Academy of Medicine Singapore, patients with hearing loss may be two to five times more likely to develop dementia, depending on the severity of their hearing loss. This is because hearing loss, when left unaddressed, may lead to increased social isolation and cognitive decline due to the lack of communication between these individuals.
In a bid to improve hearing performance in people with hearing loss, Cochlear Limited, the global leader in implantable hearing solutions, announced in August the launch of the Nucleus® Kanso® 2 Sound Processor in Singapore. This new launch reflects Cochlear’s ongoing commitment to innovation in hearing technology and empowering people to connect.
Amy Zheng, General Manager, Southeast Asia, Cochlear, said, “Cochlear is dedicated to bringing sound to people all over the world. The Nucleus Kanso 2 Sound Processor showcases Cochlear’s latest and most advanced hearing performance technology and marks a new step towards helping people in Singapore living with hearing loss to hear better. With its latest connectivity features and simple design, this new technology is designed to better meet the different needs and lifestyles of individuals and is the result of persistent efforts to improve hearing outcomes.”
Weighing only 14.2 grams, the Nucleus® Kanso® 2 Sound Processor is the world’s smallest off-the-ear cochlear implant sound processor with proven hearing performance technologies. It is the first and only off-the-ear cochlear implant sound processor to offer direct streaming from compatible Apple or Android™ devices, and is compatible with the Nucleus Smart App, enabling control of device settings, functions, and information.
The Kanso® 2 Sound Processor features an integrated rechargeable battery and the highest possible water resistance rating for any off-the-ear cochlear implant sound processor, giving users the freedom to live an active lifestyle.
To help users hear more of what they want to listen to, the Nucleus® Kanso® 2 Sound Processor features proven hearing performance technologies. Dual microphones filter out background noise to help provide better hearing performance in noise compared to a single microphone. With ForwardFocus, users can reduce noise from behind them to help them focus on conversations in front of them. SmartSound® IQ with SCAN helps users to hear more clearly in a range of listening environments by capturing sound through dual microphones, analysing surroundings, before automatically adjusting the settings for the hearing conditions.
As we prepare for the silver tsunami, many adults would soon require hearing aids and as Dr. Barrie Tan, Senior Consultant and Medical Director of Barrie Tan ENT Head & Neck Surgery said at Cochlear’s media launch, “Hearing loss is an unnecessary disability.” With the Nucleus® Kanso® 2 Sound Processor, we can enable individuals to continue maintaining their relationships, be active members of society, and retain their quality of life. The Nucleus® Kanso® 2 Sound Processor is available from August 2021.
Source: Cochlear Limited